Cetera Advisors’s Filana Therapeutics FLNA Stock Holding History

Cetera Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,444	Closed	-$238K	–	1514
2021 Q4	$238K	Buy	+5,444	New	+$285K	﹤0.01%	1235

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Cetera Advisors's FLNA Position: Q1 2022 in Review

Cetera Advisors sold out of Filana Therapeutics (FLNA) in Q1 2022, closing a stake of 5,444 shares — an estimated $238K sold.

Cetera Advisors first reported a position in FLNA in Q4 2021 and held it in 1 quarter. The position peaked at $238K in Q4 2021. 163 funds tracked by Wall St. Rank hold FLNA as of Q1 2022.

Cetera Advisors reported no remaining Filana Therapeutics position as of Q1 2022 after selling out during the quarter.
Cetera Advisors sold 5,444 Filana Therapeutics shares in Q1 2022, an estimated $238K.
Cetera Advisors first reported a position in Filana Therapeutics in Q4 2021 and held it in 1 quarter.
Cetera Advisors's Filana Therapeutics position peaked at $238K in Q4 2021.
163 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2022.

Based on Cetera Advisors's 13F filing for Q1 2022, filed 12 May 2022.